9α-フルオロメドロキシプロゲステロンアセテート (FMPA) のラットDMBA誘発乳癌の抑制効果およ びウサギ角膜法での血管新生抑制効果について

内田勝幸*、坪井 洋*、山地建人*、村田奈津子*、河野哲也*、 杉野栄一、日比野 俐、島村真理子**、及川 勉**

Cancer Letters, 154(1), 63–69 (2000).

Inhibition by 9α -Fluoromedroxyprogesterone Acetate (FMPA) against Mammary Carcinoma Induced by Dimethylbenz[a]anthracene in rats and Angiogenesis in the Rabbit Cornea - Comparison with Medroxyprogesterone Acetate

Masayuki Uchida*, Hiroshi Tsuboi*, Taketo Yamaji*, Natsuko Murata*, Tetsuya Kohno*, Eiichi Sugino, Satoshi Hibino, Mariko Shimamura**, Tsutomu Oikawa**

ABSTRACT: The effects of FMPA (9α -fluoromedroxyprogesterone acetate) on rat mammary carcinomas induced by dimethylbenz[a]anthracene (DMBA) to determine the anti-tumor activity, the effects on angiogenesis in rabbit corneal assays, and compared these results with those for MPA were investigated. From these results, FMPA was potentially more effective in the treatment of mammary carcinomas than MPA (medroxyprogesterone acetate). FMPA also displayed more potent anti-angiogenic activity than MPA by the rabbit corneal assay.

抄録 FMPAの抗腫瘍活性および血管新生抑制効果をMPAを対照とし、ラット DMBA誘発乳癌およびウサギ角膜法でそれぞれ評価した。

Department of Pharmaceutical Development, Meiji Milk Products Co. Ltd.
明治乳業 (株) 医薬開発部

** Pharmaceutical Research Center, The Tokyo Metroporitan Institute of Medical Science

東京都臨床医学総合研究所、医薬研究開発センター